Nintedanib is under clinical development by Austhera BioSciences and currently in Phase I for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase I drugs for Idiopathic Pulmonary Fibrosis have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Nintedanib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Nintedanib overview

Nintedanib (KNIN) is under development for the treatment of idiopathic pulmonary fibrosis. The drug candidate is administered through sublingual route and developed based on kinetisol technology.

Austhera BioSciences overview

Austhera BioSciences is a pharmaceutical development company that develops transformative drug candidates and novel chemical entities for the treatment of cancer and rare diseases. Austhera BioSciences is headquartered in Georgetown, Texas, the US.

For a complete picture of Nintedanib’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.